Continuous Glucose Monitoring in Infants
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04458649 |
Recruitment Status :
Recruiting
First Posted : July 7, 2020
Last Update Posted : May 15, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Neonatal Hypoglycemia | Device: Dexcom continuous glucose monitor |
Study Type : | Observational |
Estimated Enrollment : | 200 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Continuous Glucose Monitoring in Infants |
Actual Study Start Date : | October 1, 2020 |
Estimated Primary Completion Date : | September 30, 2024 |
Estimated Study Completion Date : | September 30, 2024 |

Group/Cohort | Intervention/treatment |
---|---|
No increased risk of hypoglycemia
Infants born with no obvious risk factors for hypoglycemia in the neonatal period.
|
Device: Dexcom continuous glucose monitor
Measurement of interstitial glucose |
Increased risk of hypoglycemia
Infants considered at increased risk for hypoglycemia after birth including the following criteria:
|
Device: Dexcom continuous glucose monitor
Measurement of interstitial glucose |
- Time spent with glucose <40 mg/dL [ Time Frame: The device will be worn from about 2 hours after birth until hospital discharge, up to a maximum of 10 days. It will be removed sooner if required for medical care or if the parent requests removal. ]The Dexcom continuous glucose monitors measure interstitial fluid glucose values every 5 minutes. Data obtained from the Dexcom tracings will allow us to quantify how much time both infants with no risk for hypoglycemia (defined here as <40 mg/dL) and those with risk factors for hypoglycemia spend at a blood glucose of <40 mg/dL.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Hour to 2 Hours (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Mother at least 18 years of age
- Infants born either appropriate for gestational age (AGA) or large for gestational age (LGA)
- Skin fold over superior gluteus area at least 1 inch in thickness as measured by skin calipers
Exclusion Criteria:
- Infants born small for gestational age (SGA)
- Infant birth weight <2.5 kg
- Infant BMI <10th percentile on Olsen chart
- Infants born <38 weeks gestation
- Infants with concern for intrauterine growth restriction (IUGR) and short femur length based on ultrasound
- Mother is non-English speaking

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04458649
Contact: Valentina Stanley, BS | (858) 249-5985 | vstanley@health.ucsd.edu | |
Contact: Jane Kim, MD | (858) 966-4032 |
United States, California | |
UCSD Medical Center | Recruiting |
La Jolla, California, United States, 92037 | |
Contact: Valentina Stanley, BS 858-966-4032 vstanley@health.ucsd.edu | |
Contact: Jane Kim, MD 858-966-4032 |
Principal Investigator: | Jane Kim, MD | University of California San Diego/Rady Children's Hospital |
Responsible Party: | Dr Jane Kim, Professor of Pediatrics, University of California, San Diego |
ClinicalTrials.gov Identifier: | NCT04458649 |
Other Study ID Numbers: |
191263 |
First Posted: | July 7, 2020 Key Record Dates |
Last Update Posted: | May 15, 2023 |
Last Verified: | May 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Hypoglycemia Glucose Metabolism Disorders Metabolic Diseases |